Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.
作者信息
Desoize B, Marechal F, Cattan A
机构信息
Institut Jean Godinot, Reims, France.
出版信息
Br J Cancer. 1990 Nov;62(5):840-1. doi: 10.1038/bjc.1990.390.
Abstract
摘要
相似文献
1
Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.依托泊苷在实体瘤120小时持续输注期间的临床药代动力学
Br J Cancer. 1990 Nov;62(5):840-1. doi: 10.1038/bjc.1990.390.
2
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.实体瘤患者静脉注射磷酸依托泊苷和依托泊苷后依托泊苷的药代动力学和生物等效性
J Clin Oncol. 1995 Nov;13(11):2835-41. doi: 10.1200/JCO.1995.13.11.2835.
3
Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.21天持续口服依托泊苷在实体瘤儿科患者中的药代动力学和药效学
Clin Pharmacol Ther. 1995 Jul;58(1):99-107. doi: 10.1016/0009-9236(95)90077-2.
4
Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory Investigation.在一种新的仔猪模型中将化疗药物直接注入第四脑室。实验室研究。
J Neurosurg Pediatr. 2008 May;1(5):373-80. doi: 10.3171/PED/2008/1/5/373.
5
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.在一项I期研究中，癌症患者口服前药磷酸依托泊苷后依托泊苷的生物利用度。
J Clin Oncol. 1996 Jul;14(7):2020-30. doi: 10.1200/JCO.1996.14.7.2020.
6
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.67 例儿童依托泊苷药代动力学的发展：地塞米松无作用。
Cancer Chemother Pharmacol. 2011 Mar;67(3):597-603. doi: 10.1007/s00280-010-1357-2. Epub 2010 May 20.
7
First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.拓扑替康新型前体药物CAP7.1在难治性实体瘤成人患者中的首次人体剂量递增及药代动力学研究。
Eur J Cancer. 2017 Jul;80:14-25. doi: 10.1016/j.ejca.2017.03.032. Epub 2017 May 19.
8
[Pharmacokinetics and toxicological study on the intraperitoneal administration of cisplatin and etoposide in gynecological malignancies].顺铂和依托泊苷腹腔内给药用于妇科恶性肿瘤的药代动力学及毒理学研究
Gan To Kagaku Ryoho. 1992 Sep;19(11):1843-9.
9
Intraperitoneal chemotherapy: application to upper gastrointestinal neoplasms.腹腔内化疗：在上消化道肿瘤中的应用
Acta Chir Scand Suppl. 1988;541:16-21.
10
High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.高剂量环孢素与依托泊苷联用——实体瘤患儿的毒性及药代动力学相互作用
Br J Cancer. 1998 Jun;77(12):2304-9. doi: 10.1038/bjc.1998.383.
引用本文的文献
1
Population pharmacokinetic studies in pediatrics: issues in design and analysis.儿科群体药代动力学研究：设计与分析中的问题
AAPS J. 2005 Oct 5;7(2):E475-87. doi: 10.1208/aapsj070248.
2
Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.白血病患儿中依托泊苷和依托泊苷儿茶酚的有限及优化采样策略
J Pharmacokinet Pharmacodyn. 2002 Apr;29(2):171-88. doi: 10.1023/a:1019755608555.
3
Pharmacokinetically guided administration of chemotherapeutic agents.化疗药物的药代动力学导向给药
Clin Pharmacokinet. 2000 Nov;39(5):345-67. doi: 10.2165/00003088-200039050-00004.
4
Adaptive control methods for the dose individualisation of anticancer agents.抗癌药物剂量个体化的自适应控制方法。
Clin Pharmacokinet. 2000 Apr;38(4):315-53. doi: 10.2165/00003088-200038040-00003.
5
Practical treatment guide for dose individualisation in cancer chemotherapy.癌症化疗剂量个体化实用治疗指南。
Drugs. 1998 Dec;56(6):1019-38. doi: 10.2165/00003495-199856060-00006.
6
Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.药理学知识在癌症化疗设计与监测中的益处。
Pathol Oncol Res. 1998;4(3):171-8. doi: 10.1007/BF02905246.
本文引用的文献
1
Reporting results of cancer treatment.癌症治疗结果报告。
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
2
Anticancer drug pharmacodynamics.抗癌药药效学
Cancer Chemother Pharmacol. 1985;14(3):177-83. doi: 10.1007/BF00258112.
3
Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.依托泊苷在肾功能和肝功能异常患者中的药代动力学。
Cancer Res. 1986 May;46(5):2566-71.
4
Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
J Clin Oncol. 1987 Jul;5(7):1007-14. doi: 10.1200/JCO.1987.5.7.1007.
5
The clinical pharmacology of etoposide and teniposide.依托泊苷和替尼泊苷的临床药理学
Clin Pharmacokinet. 1987 Apr;12(4):223-52. doi: 10.2165/00003088-198712040-00001.
6
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Med Oncol Tumor Pharmacother. 1986;3(2):95-9. doi: 10.1007/BF02934560.
7
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.转移性结直肠癌中持续输注氟尿嘧啶与传统推注方案的前瞻性随机对照研究：一项大西洋中部肿瘤项目研究。
J Clin Oncol. 1989 Apr;7(4):425-32. doi: 10.1200/JCO.1989.7.4.425.
8
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.依托泊苷给药的自适应控制：患者间药效学变异性的影响
Clin Pharmacol Ther. 1989 Mar;45(3):226-33. doi: 10.1038/clpt.1989.22.
9
Superiority of perfusion over bolus administration in cancer chemotherapy: proposition of a compartmental model.灌注在癌症化疗中优于推注给药：一种房室模型的提出
Med Hypotheses. 1989 May;29(1):21-4. doi: 10.1016/0306-9877(89)90161-8.
Zotero 插件